Please login to the form below
neurodegeneration
This page shows the latest neurodegeneration news and features for those working in and with pharma, biotech and healthcare.
FDA grants fast track designation to AC Immune’s Alzheimer’s disease vaccine
ability of ACI-24.060 active immunotherapy to modulate neurodegeneration at its earliest stages and offer this population a much needed therapeutic option".
Latest news
-
Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS
Results showed that those treated with Qalsody experienced a 55% reduction in plasma neurofilament light chain (NfL) – a marker of neurodegeneration – compared to a 12% increase in placebo-treated patients.
-
Eisai and Washington University to develop neurodegenerative disease therapies
Over the next five years, the partners will aim to create multiple novel therapeutic candidates and identify novel biomarkers of neurodegeneration. ... targeting the tau protein, which is closely associated with neurodegeneration in Alzheimer’s,
-
Lilly’s donanemab shows promise in early symptomatic Alzheimer's comparator study
Mark Mintun, group vice president of pain and neurodegeneration research and development, Lilly.
-
New study finds signs of dementia could be detected nine years before diagnosis
One of the reasons for this is because these conditions are often only diagnosed once symptoms appear, whereas the underlying neurodegeneration may have begun much earlier.
-
Michael J Fox Foundation awards $4.9m grant to Muna Therapeutics
Reducing neuroinflammation by blocking Kv1.3 has tremendous potential to slow or prevent neurodegeneration and disease progression,” explained Rita Balice-Gordon, chief executive officer of Muna Therapeutics.
More from news
Approximately 5 fully matching, plus 44 partially matching documents found.
Latest Intelligence
-
A roadmap to the successful treatment of Alzheimer’s disease
Two proteins – Tau and beta-amyloid – are recognised as major hallmarks of neurodegeneration: tangles and other abnormal forms of Tau protein accumulate inside the brain cells and spread between cells, while ... Secondly, it is well understood that
-
Brain power: fresh approaches to Alzheimer’s drug discovery
US biotech company Alector, which is pioneering work in immuno-neurology and novel therapeutic approaches to treating neurodegeneration, raised $176m in an initial public offering in early February. ... Alector has devoted the last five years to the
-
Deal Watch October 2018
Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.
-
Key considerations for disease- modifying Parkinson’s disease trials
dopamine due to neurodegeneration.
-
Holding on to hope for Alzheimer’s advances
abnormalities including seizures, neurodegeneration, cognitive deficits and hypomyelination…it is completely unclear whether BACE could be targeted in a manner to affect amyloid processing in a therapeutic manner, without serious
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Lilly strengthens team with in-house promotions
Importantly, this team will help us maintain focus as we work to bring forward new medicines in diabetes, cancer, immunology, neurodegeneration and pain.”.
-
Asceneuron appoints chief medical officer
He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011.
-
Nouscom appoints COO and board members
Prior to this, she was the global head of neurodegeneration at Novartis, and worked in the healthcare sector of McKinsey &Company in Chicago.
-
Polleo Pharma co-founders join Chronos Therapeutics
Dr Murray (pictured above) brings over 20 years of drug discovery and early development experience to the role, spread across a range of therapeutic areas including dermatology, inflammation, neurodegeneration, psychiatry.
-
Sanofi appoints Pfizer's Rita Balice-Gordon to lead neurobiology research
including neurodegeneration, neuroinflammation and central nervous system inherited diseases.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
What do NHS changes and the Life Sciences Vision mean for medicines?
These seven challenges (or ‘’silent pandemics’ as the LSV calls them) are neurodegeneration; early diagnosis and treatment in cancer, including immune therapies; vaccine development and manufacturing; cardiovascular disease and obesity;
-
Are we ready for an Alzheimer's disease modifying treatment
As it is easier to prevent neurodegeneration (neuron death) than to reverse it, neuroscientists are starting to look for early markers, through genetic tests or blood tests, in order to diagnose
-
Innovative approaches in the treatment of multiple sclerosis
The pathogenesis of MS consists of two key components: focal inflammatory demyelination, and neurodegeneration.
-
Innovative approaches in the treatment of multiple sclerosis
The pathogenesis of MS consists of two key components: focal inflammatory demyelination, and neurodegeneration.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- COVID-19 could be key in identifying viruses with pandemic potential
- Novo Nordisk Foundation commits €127m for new cell therapy facility
- Alzheimer’s Research UK launches ‘Change The Ending’ campaign
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
No results were found
PMHub
Create Health
A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
